Open AccessConstruction and validation of m 6 A RNA methylation regulators associated prognostic model for gastrointestinal cancer
Author(s) -
Miao Yandong,
Su Bin,
Tang Xiaolong,
Wang Jiangtao,
Quan Wuxia,
Chen Yonggang,
Mi Denghai
Publication year - 2022
Publication title -
iet systems biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.367
H-Index - 50
eISSN - 1751-8857
pISSN - 1751-8849
DOI - 10.1049/syb2.12040
Subject(s) - cancer , methylation , microrna , rna , dna methylation , gastrointestinal cancer , cancer research , biology , computational biology , oncology , medicine , gene expression , genetics , gene , colorectal cancer
N6‐methyladenosine (m 6 A) RNA methylation is correlated with carcinogenesis and dynamically possessed through the m 6 A RNA methylation regulators. This paper aimed to explore 13 m 6 A RNA methylation regulators' role in gastrointestinal cancer (GIC) and determine the risk model and prognosis value of m 6 A RNA methylation regulators in GIC. We used several bioinformatics methods to identify the differential expression of m 6 A RNA methylation regulators in GIC, constructed a prognostic model, and carried out functional enrichment analysis. Eleven of 13 m 6 A RNA methylation regulators were differentially expressed in different clinicopathological characteristics of GIC, and m 6 A RNA methylation regulators were nearly associated with GIC. We constructed a risk model based on five m 6 A RNA methylation regulators (METTL3, FTO, YTHDF1, ZC3H13, and WTAP); the risk score is an independent prognosis biomarker. Moreover, the five m 6 A RNA methylation regulators can also forecast the 1‐, 3‐ and 5‐year overall survival through a nomogram. Furthermore, four hallmarks of oxidative phosphorylation, glycolysis, fatty acid metabolism, and cholesterol homoeostasis gene sets were significantly enriched in GIC. m 6 A RNA methylation regulators were related to the malignant clinicopathological characteristics of GIC and may be used for prognostic stratification and development of therapeutic strategies.